AstraZeneca Inks $425M Deal To End Acid-Reflux Drug Claims
AstraZeneca on Tuesday said it has reached a $425 million deal to end claims in both federal and state court that its acid reflux drugs Nexium and Prilosec caused kidney injuries....To view the full article, register now.
Already a subscriber? Click here to view full article